Macrogenics (FRA:M55) Payments of Debt: €0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:M55 Macrogenics Inc FRA:M55
53 GF Score
Price €3.56
GF Value €3.40
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Macrogenics Payments of Debt?

Macrogenics FRA:M55 -4.81% 53 Payments of Debt is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:M55 with a GF Score™ of 53/100 and a GF Value™ of €3.40 (Fairly Valued). The stock has 8 warning signs investors should review.

Macrogenics's Payments of Debt for the three months ended in Mar. 2026 was €0.0 Mil.

Macrogenics's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

Macrogenics Payments of Debt Related Terms

Macrogenics Payments of Debt Historical Data

* Premium members only.

The historical data trend for Macrogenics's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Macrogenics Payments of Debt Chart

Macrogenics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Macrogenics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:M55
53GF Score
Macrogenics Inc FRA:M55
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Macrogenics Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €0.0 Mil mean?
Macrogenics (FRA:M55) has a Payments of Debt of €0.0 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Macrogenics and its competitors.
Is Macrogenics' Payments of Debt too high?
Macrogenics' current Payments of Debt is €0.0 Mil. Overall, Macrogenics has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' Payments of Debt compare to IMRX and TRDA?
Macrogenics' Payments of Debt of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Macrogenics and its competitors. Macrogenics's current Payments of Debt is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Based on GuruFocus' analysis, Macrogenics (FRA:M55) is currently considered Fairly Valued. The stock's GF Value™ is €3.40, compared to a current price of €3.56 — trading 4.7% above its estimated fair value. The current Payments of Debt is €0.0 Mil. Macrogenics' overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current Payments of Debt is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Macrogenics (FRA:M55) Overvalued in 2026?

Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued. The current stock price of €3.56 is trading 4.7% above its estimated GF Value™ of €3.40. GuruFocus considers Macrogenics to be Fairly Valued.

Key valuation signals for FRA:M55:

  • Payments of Debt: €0.0 Mil
  • GF Value™: €3.40 vs. price of €3.56 (4.7% above fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Macrogenics Business Description

Other Exchanges MGNX:USA
Address 9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
53GF Score

Get the complete analysis for FRA:M55

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.56
Price
€3.40
GF Value